May 21, 2026

FDA clears Glooko’s cloud-based insulin dosing platform

Ideating on Glooko’s existing EndoTool system, the cloud-based version is designed to support more scalable deployment across hospital settings.

Read More

May 15, 2026

FDA Grants 510(k) Clearance for Glooko’s EndoTool IV Cloud Insulin Dosing Platform

Glooko has received U.S. FDA 510(k) clearance for EndoTool IV Cloud, making it the first cloud-based, patient-specific insulin dosing platform cleared...

Read More

May 14, 2026

FDA Clears Glooko’s Cloud Platform for IV Insulin Dosing

Glooko has won FDA clearance for EndoTool IV Cloud, a cloud-based patient-specific insulin dosing platform that supports individualized insulin dosing...

Read More

May 14, 2026

Glooko wins FDA clearance for cloud-based insulin dosing platform

Glooko announced that the FDA granted 510(k) clearance for its EndoTool IV Cloud, a cloud-based, patient-specific insulin dosing platform.

Read More

May 14, 2026

FDA Clears EndoTool IV Cloud for Inpatient IV Insulin Dosing Support

The US FDA cleared the EndoTool IV Cloud, a cloud-based version of parent company Glooko’s inpatient intravenous insulin dosing decision-support platform,...

Read More

May 12, 2026

MyLife Diabetes Care, Glooko expand partnership

Glooko and MyLife Diabetes Care announced that they agreed to expand their partnership centered around diabetes management products.

Read More